Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,595.00
Bid: 1,594.00
Ask: 1,594.50
Change: -13.50 (-0.84%)
Spread: 0.50 (0.031%)
Open: 1,604.50
High: 1,609.00
Low: 1,586.50
Prev. Close: 1,608.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of GSK 2019 Form 20-F

9 Mar 2020 07:00

RNS Number : 3525F
GlaxoSmithKline PLC
09 March 2020
 

 

GlaxoSmithKline plcAnnual Report 2019 on Form 20-F

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 06 March 2020 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2019. GSK's 2019 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk.

A hard copy version of the GSK 2019 Annual Report, together with the Notice of Annual General Meeting will be available on or about 23 March 2020.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2020, free of charge, by either:

(i) writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);

(ii) writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 800 990 1135 (US toll free) or +1 651 453 2128 (outside the US); or

(iii) contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

Victoria WhyteCompany Secretary06 March 2020

 

Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2019.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKABDDBKBONK
Date   Source Headline
8th Jul 20226:04 pmRNSDirector/PDMR Shareholding
8th Jul 20225:30 pmRNSDirector/PDMR Shareholding
8th Jul 20223:53 pmRNSDirector/PDMR Shareholding
8th Jul 20223:33 pmRNSDirector/PDMR Shareholding
8th Jul 20223:10 pmRNSDirector/PDMR Shareholding
6th Jul 20224:30 pmRNSResult of General Meeting
6th Jul 202210:11 amRNSDirector/PDMR Shareholding
5th Jul 202212:43 pmRNSGSK disclose discontinued operations from Q2 2022
5th Jul 20229:45 amRNSDirector/PDMR Shareholding
5th Jul 20229:30 amRNSDirector/PDMR Shareholding
1st Jul 20223:27 pmRNSTotal Voting Rights
1st Jul 20222:45 pmRNSGSK completes acquisition of Sierra Oncology
28th Jun 20225:56 pmRNSDirector/PDMR Shareholding
28th Jun 20227:00 amRNSGSK files Shingrix 18+ at risk indication in Japan
27th Jun 20224:08 pmRNSDirector/PDMR Shareholding
24th Jun 20223:44 pmRNSDirector/PDMR Shareholding
16th Jun 202210:58 amRNSDirector/PDMR Shareholding
10th Jun 20227:00 amRNSPositive phase III data for GSK’s RSV OA vaccine
9th Jun 20224:28 pmRNSDirector/PDMR Shareholding
7th Jun 20225:17 pmRNSDirector/PDMR Shareholding
7th Jun 202212:00 pmEQSHardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
6th Jun 20227:00 amRNSUS FDA approval of Priorix
1st Jun 20224:55 pmRNSTotal Voting Rights
1st Jun 20221:00 pmRNSDemerger update: Publication of Documents
1st Jun 20227:00 amRNSDemerger update: Submission of Documents to FCA
31st May 20227:00 amRNSGSK to acquire Affinivax, Inc.
30th May 202210:00 amRNSFurther appointments to Designate Haleon Board
27th May 20227:00 amRNSGSK Cervarix two-dose schedule approved by NMPA
25th May 20223:41 pmPRNDirector/PDMR Shareholding
23rd May 20223:21 pmRNSDirector/PDMR Shareholding
19th May 202210:02 amRNSIain Mackay - External Appointment
16th May 20222:00 pmRNSChange of name to GSK plc
13th May 20225:13 pmRNSDirector/PDMR Shareholding
12th May 20228:58 amRNSDirector/PDMR Shareholding
11th May 20225:17 pmRNSBlock listing Interim Review
9th May 20222:53 pmRNSDirector/PDMR Shareholding
4th May 20225:49 pmRNSResult of AGM
4th May 202210:00 amRNSDirectorate Change
3rd May 20224:52 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNS1st Quarter Results
26th Apr 20229:32 amRNSDirector/PDMR Shareholding
19th Apr 20227:00 amRNSDaprodustat application accepted for review by FDA
14th Apr 20222:23 pmRNSDirector/PDMR Shareholding
14th Apr 20222:15 pmRNSDirector/PDMR Shareholding
14th Apr 20221:29 pmRNSDirector/PDMR Shareholding
13th Apr 20225:11 pmRNSDirector/PDMR Shareholding
13th Apr 20229:32 amRNSDirector/PDMR Shareholding
13th Apr 20227:00 amRNSGSK agrees to acquire Sierra Oncology for $1.9bn
12th Apr 20225:10 pmRNSDirector/PDMR Shareholding
12th Apr 20224:23 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.